CERVIVA is a multi-investigator collaboration encompassing researchers at several national and international academic institutions, health agencies, and commercial diagnostic and biotechnology companies. The purpose of the consortium is to advance high quality peer-reviewed research programmes in the area of HPV associated diseases.
CERVIVA was established in 2005 and was initially funded by the HRB Health Services Research Award scheme to perform high quality research in the area of cervical screening in Ireland, with an overarching aim of supporting CervicalCheck [the National Cervical Screening Programme]. Through phase 1 funding, CERVIVA has been a very successful health services based research consortium, which has effectively bridged the gap between academic research and health services and clinical research.
In phase 2, CERVIVA 2, [which was funded initially through the HRB ICE programme and then the HRB CARG programme], builds on existing capacities and competencies to further develop and expand emerging research topics of interest to cancer screening in Ireland. This is being achieved through a multidisciplinary approach focussing on the areas of health economics, molecular biology/epidemiology, and health psychology.
CERVIVA gratefully acknowledges the support of the Health Research Board, Irish Cancer Society, CervicalCheck, the National Cervical Screening Programme, the National Cancer Registry Ireland, Molecular Medicine Ireland, the Coombe Women and Infants University Hospital, and Friends of the Coombe.